SBIR-STTR Award

Confocal and Autofluorescence Imaging of Macular Degeneration Using a Low Cost Digital Imager
Award last edited on: 12/5/2019

Sponsored Program
SBIR
Awarding Agency
NIH : NEI
Total Award Amount
$1,387,702
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Matthew S Muller

Company Information

Aeon Imaging LLC

501 South Madison Street Suite 103
Bloomington, IN 47403
   (812) 822-2048
   N/A
   www.aeonimaging.com
Location: Single
Congr. District: 09
County: Monroe

Phase I

Contract Number: 1R43EY024186-01
Start Date: 3/1/2014    Completed: 2/28/2015
Phase I year
2014
Phase I Amount
$200,000
The overall goal of the proposed SBIR Phase I research is to build and begin initial evaluation of a low cost, portable retinal camera used to detect age-related macular degeneration and other retinal degenerations. Age-related macular degeneration remains the most common cause of permanent vision loss in the US and industrialized countries. The specialized imaging techniques provide far better detection of key lesions, compared to color fundus photography, and even this basic technology is not available for all patients. New treatments do save sight, using portable lasers and injectable drugs, but elderly patients must often travel to centers because the expensive diagnostic equipment is not readily available. Early detection must lead seamlessly from a patient's eye care provider to vision-saving treatment and must be available to the underserved and those who do not drive. Aeon Imaging LLC, in partnership with the Indiana University School of Optometry, is addressing the public health challenge of providing eyecare to the elderly and underserved by developing cost-effective cameras that are readily used with internet-based telemedicine platforms. In this new proposal, Aeon seeks to optimize its low cost and portable technology based on digital light projection for use in older eyes that have small pupils and potentially poor quality ocular media. Aeon's new camera provides high contrast, confocal views of the retina in natural appearing red/green color images, or monochrome in either red or green, avoiding blue light. Near infrared illumination will be added. Both scattered light imaging and fundus autofluorescence imaging, will be added as advanced features. These techniques enhance the visualization of features beneath the retina, without the need for injection of dye. The compact and lightweight, microprocessor controlled, internet ready camera is detachable from a standard slit- lamp style alignment base for ease of transport. The projected price is well below competing products, with image contrast anticipated to be unparalleled in the low cost camera field. The high contrast and sharp images are due to the patented method using sequential presentation of strips of light and the confocal aperture afforded by the rolling shutter of the CMOS detector chip. Data will be automatically encrypted and uploaded to secure servers for review and referral recommendations. The aging of population, together with the changes in the US health care system, make the need for lower cost but high quality products an urgent one. Thus, screening for symptoms of age-related macular degeneration that have recently been treated more successfully, along with providing early detection so that those patients needing monitoring can receive priority, lead to improved vision for the most common cause of irreversible blindness in the US.

Public Health Relevance Statement:


Public Health Relevance:
Aeon Imaging, LLC, will build and test a low cost and portable retinal camera that uses novel technology based on digital light projection, to provide detection of age-related macular degeneration. Advanced imaging techniques, including scattered light imaging and fundus auto fluorescence imaging, will be implemented in a design optimized for the eyes of older patients. The novel camera has a design that provides high contrast images with a cost and footprint aimed at reducing barriers to early diagnosis and careful monitoring.

Project Terms:
Address; Age; Age related macular degeneration; Aging; Area; base; Blindness; Blood Circulation; cardiovascular risk factor; Cardiovascular system; Caring; Clinical; Color; Complex; cost; cost effective; Costs and Benefits; Data; design; Detection; detector; Developed Countries; Diagnostic Equipment; digital; Disease; Drusen; Dyes; Early Diagnosis; Elderly; Electronics; Epithelial; Evaluation; Eye; Family; flexibility; fluorescence imaging; Fundus; Fundus photography; Genotype; Goals; Health; Healthcare Systems; Human; Image; Imagery; Imaging Techniques; improved; Indiana; Individual; Inflammation; Inflammatory; inherited retinal degeneration; Injectable; Injection of therapeutic agent; instrumentation; Internet; Lasers; Lead; Legal patent; Lesion; Life; Light; light scattering; Lighting; Link; Lipofuscin; macula; Macular degeneration; Masks; Measurement; Mechanics; medical specialties; Methodology; Methods; Microprocessor; Miosis disorder; Monitor; Mutation; Mydriatics; Natural History; new technology; novel; older patient; Optical Coherence Tomography; Optics; Optometry; Pathway interactions; Patients; Pharmaceutical Preparations; Phase; Photoreceptors; Pigmentation physiologic function; Pigments; Population; population based; portability; Price; Process; programs; prototype; Provider; public health medicine (field); public health relevance; Recommendation; Recording of previous events; Reference Standards; Relative (related person); Reporting; Research; Resolution; Retina; Retinal; Retinal Degeneration; Retinal Pigments; Risk; Risk Factors; Scanning; Schools; screening; Secure; Simulate; Small Business Innovation Research Grant; Smoking; Source; Stargardt's disease; Structure of retinal pigment epithelium; Symptoms; Techniques; Technology; Telemedicine; Testing; theories; Travel; Universities; Vision

Phase II

Contract Number: 2R44EY024186-02A1
Start Date: 4/1/2018    Completed: 3/31/2020
Phase II year
2018
(last award dollars: 2019)
Phase II Amount
$1,187,702

The overall goal of the proposed SBIR Phase II research is to build and evaluate a low cost, multi-mode retinal camera used to detect and manage causes of macular impairment. Age-related macular degeneration (AMD) remains the most common cause of permanent vision loss in the US and many industrialized countries. Treatments with portable lasers and injectable drugs can save sight, but early detection and careful monitoring is essential to help maintain visual acuity and avoid over-treating with injectables. Specialized imaging techniques, such as optical coherence tomography (OCT) and autofluorescence (AF) imaging, have been developed that provide better detection of key lesions than flood-illuminated color fundus photography, but is not available to all due to their high cost. This creates a scarcity of OCT and AF imaging equipment at primary care and non-specialty eye clinics, which forces many elderly patients to travel to tertiary centers to obtain monitoring and treatment. In this Phase II proposal, Aeon builds on a successful Phase I project by enhancing its novel Digital Light Ophthalmoscope (DLO) for the multimodal detection of lesions associated with age-related macular degeneration (AMD). Specifically, we will incorporate a custom near infrared (NIR) illumination module to perform multiply scattered light imaging for the detection of disruptions in the RPE layer such as drusen (Aim 1). We will also develop and test a novel and cost-effective structured light imaging method to create en face depth sectioned images of the retina, generating coarse topographic measurements of retinal thickness and height that will be suitable for the detection of treatable exudation (Aim 2). The location of drusen and thickness of exudative regions will be evaluated in patients with AMD, plus retinal degenerations and diabetes, and 70 normal subjects, then compared to SD-OCT (Aim 3). Finally, images will be taken of the same subjects using Aeon's Phase I autofluorescence system (DLO-AF) and compared to OCT to determine the cost-benefit of incorporating autofluorescence (AF) imaging functionality into our DLO system. The aging of the population make the need for lower cost but high quality products an urgent one. Aeon Imaging LLC, in partnership with the Indiana University School of Optometry, is addressing the public health challenge of providing eye care to the elderly and underserved by developing cost-effective cameras that can be readily used in small practices, satellite offices, or with internet-based telemedicine platforms.

Public Health Relevance Statement:
Project Narrative – EY024186 Aeon Imaging, LLC, will build and test a low cost retinal camera that uses novel technology based on digital light projection, to provide detection of age-related macular degeneration. Advanced imaging techniques, including scattered light imaging and fundus autofluorescence imaging, will be implemented in a design optimized for the eyes of older patients. The novel camera has a design that provides high contrast images with a cost and footprint aimed at reducing barriers to early diagnosis and careful monitoring.  

Project Terms:
Address; Adoption; Age related macular degeneration; Aging; aging population; Anterior; Asians; Atrophic; Attenuated; base; Blindness; Blood Circulation; Caliber; Caring; Cataract; Clinic; Clinical; Color; Complex; Computer software; contrast imaging; cost; cost effective; Costs and Benefits; Custom; design; Detection; Developed Countries; Diabetes Mellitus; diabetic patient; digital; Drusen; Early Diagnosis; Edema; Elderly; epidemiology study; Epithelial; Equipment; Excision; Eye; flexibility; Floods; Fundus; Fundus photography; Goals; Gold; Height; Hyperpigmentation; Image; imager; Imagery; imaging detection; imaging modality; imaging system; Imaging Techniques; Imaging technology; Impairment; in vivo; Indiana; Individual; Inflammation; Inflammatory; Injectable; Internet; Lasers; Lead; Legal patent; lens; Lesion; Light; light scattering; Lighting; Link; Lipofuscin; Liquid substance; Location; Low income; macula; Macular degeneration; Maps; Measurement; Measures; Medicaid; Medicare; Methods; Modeling; Monitor; multimodality; new technology; novel; older patient; Older Population; Ophthalmoscopes; Optical Coherence Tomography; Optometry; Pathway interactions; Patients; Performance; performance tests; Pharmaceutical Preparations; Phase; Pigmentation physiologic function; Population; portability; Primary Health Care; Process; Public Health; Pupil; Refractive Errors; Reproducibility; Research; Resolution; Retina; Retinal; Retinal Degeneration; Retinal Diseases; retinal imaging; Retinal Photoreceptors; Retinal Pigments; S Phase; Schools; screening; Small Business Innovation Research Grant; Source; Structure; Structure of retinal pigment epithelium; Surface; System; Technology; Telemedicine; Testing; theories; Thick; Tissues; Traction; Travel; Universities; Vision; Visual Acuity; Visual impairment; Width